The 2021 San Antonio Breast Cancer Symposium (SABCS) was held from December 7 to 10 in San Antonio, Texas, and online. In this podcast, Norah Lynn Henry, MD, PhD, FASCO, discusses results and updates from research in treating breast cancer and managing its side effects presented at the conference.

  • Results from the DESTINY-Breast03 phase III clinical trial, which is comparing how well 2 targeted therapy drugs, trastuzumab deruxtecan (Enhertu) versus ado-trastuzumab emtansine (Kadcyla), work in delaying cancer growth and shrinking the cancer in people with HER2-positive metastatic breast cancer that has spread to the brain [2:38].

  • Findings from the EMERALD phase III clinical trial, which is studying how well a new hormone therapy drug called elacestrant works in treating people with metastatic hormone receptor-positive breast cancer after the cancer has worsened during previous treatment with targeted therapy and hormone therapy [3:57].

  • Updates from 2 previously presented studies in early-stage breast cancer. The first studied the effects of adding immunotherapy to neoadjuvant chemotherapy in people with stage 2 or stage 3 triple-negative breast cancer. The second studied the use of chemotherapy in postmenopausal people with hormone receptor-positive, HER2-negative breast cancer [5:00].

  • Results from a large clinical trial examining whether the diabetes drug metformin (multiple brand names) can decrease the risk of breast cancer recurrence, especially in people with hormone receptor-positive breast cancer [5:41].

  • Findings from a study evaluating how common lymphedema was in Asian, Black, and white people who had been diagnosed with breast cancer and had received an axillary lymph node dissection [6:05].  

Dr. Henry is an associate professor in the University of Michigan’s Division of Hematology/Oncology in the Department of Internal Medicine. She is the breast oncology disease lead at the Rogel Cancer Center. Dr. Henry specializes in the care of patients with all stages of breast cancer. She is the 2022 Cancer.Net Associate Editor for Breast CancerView Dr. Henry’s disclosures.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content.